Krystal Biotech Financials - Benzinga

Krystal Biotech Inc

KRYSNASDAQ

Trade with Public

Trade with Public

$342.56

-8.70-2.48%

Last update: Sep 9, 2:24 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Krystal Biotech Financials

Krystal Biotech (KRYS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Krystal Biotech Q2 EPS $1.79 Beats $1.66 Estimate, Sales $119.222M Miss $121.061M Estimate

Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.66 by 7.83 percent. This is a 38.76 percent increase over earnings of $1.29 per share from the

Benzinga Newsdesk

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Krystal Biotech (KRYS) reported strong Q1 earnings, beating analyst estimates and with potential for future growth. Shares fell 1% on Tuesday.

Avi Kapoor

Earnings Scheduled For May 4, 2026

Benzinga Insights

PRO
Krystal Biotech Q1 EPS $1.83 Beats $1.39 Estimate, Sales $116.357M Beat $112.132M Estimate

Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 by 31.65 percent. This is a 52.5 percent increase over earnings of $1.20 per share from the

Benzinga Newsdesk

Krystal Biotech: Q4 Earnings Insights

Benzinga Insights

PRO
Krystal Biotech Q4 EPS $1.70 Beats $1.39 Estimate, Sales $107.105M Beat $105.338M Estimate

Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.39 by 22.21 percent. This is a 11.84 percent increase over earnings of $1.52 per share from the

Benzinga Newsdesk